Sanara MedTech's Q3 Loss Widens on Discontinued Operations Impairment

TL;DR

**SMTI took a massive hit from ditching its failing THP segment, but the core surgical business is growing, making it a speculative turnaround play.**

AI Summary

Sanara MedTech Inc. (SMTI) reported a significant net loss of $30,411,153 for the three months ended September 30, 2025, a substantial increase from the $2,857,768 net loss in the same period of 2024. This was primarily driven by a $31,246,601 net loss from discontinued operations, which included an asset impairment charge of $26,472,407 related to the wind-down of its Tissue Health Plus (THP) segment. Despite this, net revenue from continuing operations increased to $26,333,819 for the three months ended September 30, 2025, up from $21,671,599 in 2024, representing a 21.5% growth. Gross profit also rose to $24,459,605 from $19,679,612 year-over-year. Operating income from continuing operations improved significantly to $2,941,240, compared to $778,537 in the prior year. However, interest expense more than doubled to $1,818,105 from $927,577, reflecting increased long-term debt which grew to $45,089,787 as of September 30, 2025, from $30,689,290 at December 31, 2024. The company's total assets decreased from $88,091,992 to $71,088,648, and total shareholders' equity plummeted from $38,911,962 to $6,140,534 over the same period.

Why It Matters

Sanara MedTech's decision to discontinue its Tissue Health Plus (THP) segment, resulting in a massive $26.5 million asset impairment charge, signals a strategic pivot to focus solely on its Sanara Surgical segment. For investors, this move, while painful in the short term due to the significant net loss, could streamline operations and potentially improve future profitability by shedding a persistently loss-making division. Employees within the THP segment face job uncertainty as operations wind down through the end of 2025. Customers of THP will need to seek alternative providers, while Sanara Surgical customers may benefit from a more focused and potentially better-resourced company. In the competitive medical technology market, this strategic consolidation could allow Sanara MedTech to better compete with larger players by concentrating its R&D and sales efforts on its core surgical products like CellerateRX Surgical and BIASURGE Advanced Surgical Solution.

Risk Assessment

Risk Level: high — The company reported a net loss of $30,411,153 for the three months ended September 30, 2025, primarily due to a $26,472,407 asset impairment charge from discontinued operations. Total shareholders' equity has dramatically decreased from $38,911,962 at December 31, 2024, to $6,140,534 at September 30, 2025, indicating significant financial strain and reduced buffer against future losses. The substantial increase in long-term debt to $45,089,787 from $30,689,290 also raises concerns about financial leverage.

Analyst Insight

Investors should closely monitor Sanara MedTech's performance in its continuing Sanara Surgical segment for sustained revenue growth and improved profitability, as the THP segment wind-down is expected to conclude by year-end 2025. Evaluate the company's ability to manage its increased long-term debt and assess if the strategic focus on surgical products translates into positive net income in upcoming quarters.

Financial Highlights

debt To Equity

7.34

revenue

$26,333,819

operating Margin

11.17%

total Assets

$71,088,648

total Debt

$45,089,787

net Income

-$30,411,153

eps

-$3.52

gross Margin

92.88%

revenue Growth

+21.5%

Revenue Breakdown

Key Numbers

• $30,411,153 — Net loss attributable to Sanara MedTech shareholders (For the three months ended September 30, 2025, significantly higher than $2,857,768 in 2024.)
• $26,472,407 — Asset impairment charge (Related to discontinued operations in Q3 2025.)
• $26,333,819 — Net Revenue from continuing operations (For the three months ended September 30, 2025, up 21.5% from $21,671,599 in 2024.)
• $2,941,240 — Operating income from continuing operations (For the three months ended September 30, 2025, a significant improvement from $778,537 in 2024.)
• $45,089,787 — Long-term debt (As of September 30, 2025, an increase from $30,689,290 at December 31, 2024.)
• $6,140,534 — Total shareholders' equity (As of September 30, 2025, a sharp decline from $38,911,962 at December 31, 2024.)
• $1,818,105 — Interest expense (For the three months ended September 30, 2025, more than double the $927,577 from 2024.)
• $71,088,648 — Total assets (As of September 30, 2025, down from $88,091,992 at December 31, 2024.)
• $0.10 — Basic EPS from continuing operations (For the three months ended September 30, 2025, a positive shift from $(0.02) in 2024.)
• $(3.52) — Basic EPS from net loss (For the three months ended September 30, 2025, significantly worse than $(0.34) in 2024.)

Key Players & Entities

• Sanara MedTech Inc. (company) — Registrant
• Tissue Health Plus (company) — Discontinued operating segment
• Sanara Surgical (company) — Continuing operating segment
• Rochal Technologies (company) — In-house research and development team
• CellerateRX Surgical Activated Collagen (company) — Lead soft tissue repair product
• BIASURGE Advanced Surgical Solution (company) — Sterile no-rinse, advanced surgical solution
• BiFORM (company) — Osteoconductive, bioactive, porous implant
• ALLOCYTE Plus (company) — Human allograft cellular bone matrix
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Capital Market (regulator) — Exchange where SMTI is registered

FAQ

Risk Factors

• Significant Net Loss and Equity Erosion [high — financial]: The company reported a net loss of $30,411,153 for Q3 2025, a substantial increase from $2,857,768 in Q3 2024. This was heavily impacted by a $26,472,407 asset impairment charge related to discontinued operations. Total shareholders' equity has plummeted from $38,911,962 at December 31, 2024, to $6,140,534 as of September 30, 2025.
• Increased Debt Burden [high — financial]: Long-term debt has risen significantly to $45,089,787 as of September 30, 2025, from $30,689,290 at the end of 2024. This has led to a more than doubling of interest expense to $1,818,105 in Q3 2025 compared to $927,577 in the prior year.
• Discontinued Operations Impact [medium — operational]: The significant net loss in Q3 2025 is largely attributable to discontinued operations, including a substantial asset impairment charge of $26,472,407 for the wind-down of the Tissue Health Plus (THP) segment. This indicates strategic challenges and potential write-downs.
• Declining Asset Base [medium — financial]: Total assets have decreased from $88,091,992 at December 31, 2024, to $71,088,648 as of September 30, 2025. This reduction, coupled with the equity decline, suggests asset divestitures or impairments impacting the company's financial structure.

Industry Context

Sanara MedTech operates in the medical technology sector, focusing on wound care and related solutions. The industry is characterized by innovation, regulatory oversight, and competition from both established players and emerging companies. Trends include a growing demand for advanced wound care products driven by an aging population and increasing prevalence of chronic diseases.

Regulatory Implications

As a medical technology company, Sanara MedTech is subject to stringent regulations from bodies like the FDA. Compliance with quality standards, product approvals, and post-market surveillance are critical. Any failure to meet these regulatory requirements can lead to product recalls, fines, and reputational damage.

What Investors Should Do

1. Monitor the performance and wind-down costs of discontinued operations.
2. Analyze the sustainability of revenue growth in continuing operations.
3. Assess the company's debt management strategy and refinancing capabilities.
4. Evaluate the impact of declining shareholders' equity on financial stability.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported significant net loss of $30,411,153, driven by discontinued operations and asset impairment, despite revenue growth in continuing operations.
• 2025-09-30: Balance Sheet Date — Total assets decreased to $71,088,648 and shareholders' equity fell sharply to $6,140,534, while long-term debt increased to $45,089,787.
• 2024-09-30: End of Q3 2024 — Reported a net loss of $2,857,768 and lower revenue of $21,671,599 from continuing operations.
• 2024-12-31: End of Fiscal Year 2024 — Shareholders' equity stood at $38,911,962 and long-term debt was $30,689,290.

Glossary

Discontinued Operations

A component of a business that has been disposed of or is classified as held for sale, and whose results are reported separately from continuing operations. (A significant asset impairment charge of $26,472,407 related to the wind-down of the Tissue Health Plus segment impacted the overall net loss.)

Asset Impairment Charge

A reduction in the carrying value of an asset when its fair value is less than its book value, indicating a permanent decline in value. (A charge of $26,472,407 was recognized due to the wind-down of the THP segment, significantly contributing to the net loss.)

Continuing Operations

The normal, ongoing business activities of a company that are expected to continue into the future. (Revenue from continuing operations grew by 21.5% to $26,333,819, and operating income improved significantly, indicating strength in the core business.)

Shareholders' Equity

The residual interest in the assets of an entity after deducting all its liabilities; represents the net worth of the company. (Shareholders' equity has drastically decreased from $38,911,962 to $6,140,534, highlighting a significant erosion of the company's net worth.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, Sanara MedTech Inc. has demonstrated robust revenue growth of 21.5% in its continuing operations, with net revenue reaching $26,333,819. Operating income from continuing operations also saw a significant improvement. However, this positive operational performance is overshadowed by a substantial increase in net loss, largely due to a $26,472,407 asset impairment charge related to discontinued operations. Furthermore, the company's financial structure has weakened, with a notable increase in long-term debt to $45,089,787 and a drastic reduction in total shareholders' equity to $6,140,534.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value SMTI The Nasdaq Capital

Filing Documents

• form10-q.htm (10-Q) — 1324KB
• ex31-1.htm (EX-31.1) — 17KB
• ex31-2.htm (EX-31.2) — 17KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 8KB
• 0001493152-25-021894.txt ( ) — 8391KB
• smti-20250930.xsd (EX-101.SCH) — 58KB
• smti-20250930_cal.xml (EX-101.CAL) — 82KB
• smti-20250930_def.xml (EX-101.DEF) — 259KB
• smti-20250930_lab.xml (EX-101.LAB) — 560KB
• smti-20250930_pre.xml (EX-101.PRE) — 441KB
• form10-q_htm.xml (XML) — 1333KB

– Financial Information

Part I – Financial Information 3

Financial Statements

Item 1. Financial Statements 3 Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 3 Consolidated Statements of Operations (Unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 4 Consolidated Statements of Changes in Shareholders' Equity (Unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 5 Consolidated Statements of Cash Flows (Unaudited) for the Nine Months Ended September 30, 2025 and 2024 6 Notes to Unaudited Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 39

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 54

Controls and Procedures

Item 4. Controls and Procedures 54

– Other Information

Part II – Other Information 55

Legal Proceedings

Item 1. Legal Proceedings 55

Risk Factors

Item 1A. Risk Factors 55

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 55

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 55

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 55

Other Information

Item 5. Other Information 55

Exhibits

Item 6. Exhibits 56

Signatures

Signatures 57 Sanara, Sanara MedTech, our logo and our other trademarks or service marks appearing in this report are the property of Sanara MedTech Inc. Trade names, trademarks and service marks of other companies appearing in this report are the property of their respective owners. Solely for convenience, the trademarks, service marks and trade names included in this report are without the , or other applicable symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. Unless otherwise indicated, "Sanara MedTech," "Sanara," the "Company," "our," "us," or "we," refer to Sanara MedTech Inc. and its consolidated subsidiaries. 2 Table of Contents Part I - Financial Information ITEM 1. FINANCIAL STATEMENTS SANARA MEDTECH INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, 2025 December 31, 2024 Assets Current assets Cash $ 14,939,646 $ 15,878,295 Accounts receivable, net 12,085,845 12,408,819 Accounts receivable – related parties - 40,566 Accounts receivable - 40,566 Inventory, net 3,385,956 2,753,032 Convertible loan receivable - 1,101,478 Prepaid and other assets 714,115 1,022,464 Current assets related to discontinued operations (Note 3) 100,117 101,334 Total current assets 31,225,679 33,305,988 Long-term assets Intangible assets, net 21,100,783 23,481,095 Goodwill 3,601,781 3,601,781 Investment in equity securities 12,588,476 6,212,945 Right of use assets – operating leases 2,154,721 1,447,907 Property and equipment, net 417,208 432,317 Long-term assets related to discontinued operations (Note 3) - 19,609,959 Total long-term assets 39,862,969 54,786,004 Total assets $ 71,088,648 $ 88,091,992 Liabilities and shareholders' equity Current liabilities Accounts pa

View Full Filing

View this 10-Q filing on SEC EDGAR